Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice

M Inomata, T Tsuda, T Ichikawa, M Matsumoto… - Thoracic …, 2023 - Wiley Online Library
Objective Studies have suggested the potential efficacy of immune checkpoint inhibitors
(ICIs) for pulmonary sarcomatoid carcinoma. This multicenter observational study was …

The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: A multicenter retrospective study.

WEI Jing-Wen, HAO Yue, J Xiang… - …, 2022 - search.ebscohost.com
Pulmonary sarcomatoid carcinoma (PSC) is an aggressive and poorly differentiated type of
non-small cell lung carcinoma. Because of the rarity of PSC, the efficacy and toxicity of …

[PDF][PDF] Asbestos Exposure and Development of Pulmonary Pleomorphic Carcinoma in a Non-smoker: A Rare Non-small Cell Lung Cancer

AL Alejo, RA Patel, KK Pandya, K Bodrya, L Goldstein… - Cureus, 2023 - cureus.com
Pulmonary pleomorphic carcinoma (PPC) is a subtype of non-small cell lung cancer that is
extremely rare and carries a poor prognosis due to its inadequate response to treatment …

[PDF][PDF] 臨床腫瘍部

林龍二, 梶浦新也, 三輪敏郎, 村上望, 中嶋和仙… - 2022 - toyama.repo.nii.ac.jp
− 365− among children, adolescents and young adults in the Hokushin region, Japan,
between 2010 and 2015. Jpn J Clin Oncol. 2021 Nov 16; doi: 10.1093/jjco/hyab174.[Online …